{
  "abstract": "Filtering bleb scarring after glaucoma filtration surgery (GFS) remains the leading cause of surgical failure, and current antimetabolites are limited by non-selective cytotoxicity that restricts their long-term use. Research on skin and lung fibrosis has accumulated extensive experience in antifibrotic mechanisms and therapeutic approaches. These tissues share a common transforming growth factor-beta (TGF-β)-driven program of fibroblast activation and extracellular matrix (ECM) remodeling with Tenon capsule fibroblasts, providing a theoretical basis for translating antifibrotic strategies across organs. From a cross-organ translational medicine perspective, this review systematically summarizes progress in translating antifibrotic research from skin and lung fibrosis to antiscarring therapy for GFS, focusing on four aspects: shared fibrotic mechanisms; repurposed approved drugs and emerging molecular targets; local drug delivery systems (DDS); and ophthalmology-specific translational challenges. It also highlights mechanotransduction via Yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ), lysyl oxidase (LOX)-mediated ECM crosslinking, and the translational potential of local sustained-release delivery in filtering blebs. Building on this foundation, we propose that multi-target combination therapy, precision local delivery, and individualized antiscarring strategies based on biomarkers such as aqueous humor TGF-β ₂ may represent important future directions for improving the long-term success rate of GFS.",
  "abstract_shown": true,
  "affiliations": [
    "The First Clinical College, Guangdong Medical University",
    "Department of Ophthalmology, Affiliated Hospital of Guangdong Medical University"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Xiaolu Zhong"
    },
    {
      "affs": [
        1
      ],
      "name": "Guiling Zhao"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2vwh09wnn4fsb.bib",
  "cited_by": 0,
  "doi": "10.3389/fphar.2026.1979114",
  "fulltext_url": null,
  "id": "2vwh09wnn4fsb",
  "issns": [
    "1663-9812"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1979114/full",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2731|Glaucoma and retinal disorders"
    ]
  ],
  "openalex": "W7223688089",
  "pdf_url": "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1979114/pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-26",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/2vwh09wnn4fsb.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:06Z",
      "native_id": "10.3389/fphar.2026.1979114",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1979114/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:1663-9812",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "Cross-organ translation of antifibrotic strategies from skin and lung fibrosis to glaucoma filtration surgery",
  "title_text": "Cross-organ translation of antifibrotic strategies from skin and lung fibrosis to glaucoma filtration surgery",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:06Z",
  "url": "https://research.draconitic.com/paper/2vwh09wnn4fsb",
  "venue": "Frontiers in Pharmacology",
  "versions": []
}